{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:50:07Z","timestamp":1769158207900,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007309","name":"Japanese Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007309","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejso.2019.11.520","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T02:26:50Z","timestamp":1575426410000},"page":"868-875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Hiroko","family":"Machida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriomi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kaneuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2019.11.520_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer biol med"},{"key":"10.1016\/j.ejso.2019.11.520_bib2","article-title":"Epithelial ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer and less common histopathologies","year":"2019","journal-title":"NCCN guideline version1"},{"key":"10.1016\/j.ejso.2019.11.520_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"26","author":"Winter","year":"2008","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clini Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejso.2019.11.520_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"332","author":"van der Burg","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.11.520_bib7","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.11.520_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1471-0528.1994.tb13080.x","article-title":"Intervention debulking surgery in advanced epithelial ovarian cancer","volume":"101","author":"Redman","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ejso.2019.11.520_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.11.520_bib10","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clini Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib11","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clini Res ed)"},{"key":"10.1016\/j.ejso.2019.11.520_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynaecol Obstet: Off Organ Int Fed Gynaecol Obstet"},{"key":"10.1016\/j.ejso.2019.11.520_bib13","author":"National Institutes of Health National Cancer Institute published"},{"key":"10.1016\/j.ejso.2019.11.520_bib14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejso.2019.11.520_bib15","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ejso.2019.11.520_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial","volume":"10","author":"Woods","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejso.2019.11.520_bib17","unstructured":"Cochrane handbook for systematic reviews of interventions, [chapter 8] (accessed June 5th 2019)."},{"key":"10.1016\/j.ejso.2019.11.520_bib18","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ejso.2019.11.520_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clini Res ed)"},{"key":"10.1016\/j.ejso.2019.11.520_bib20","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ (Clini Res ed)"},{"key":"10.1016\/j.ejso.2019.11.520_bib21","first-page":"830","article-title":"A\u00a0randomised control trial of systematic lymphadenectomy versus removal of bulky nodes at interval debulking for advanced epithelial ovarian cancer","volume":"28","author":"Sebastian AT","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.11.520_bib22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.11.520_bib23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A\u00a0randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.11.520_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","article-title":"Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial","volume":"70","author":"Rouzier","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2019.11.520_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ygyno.2016.11.021","article-title":"Optimizing the treatment of ovarian cancer: neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection","volume":"144","author":"Gill","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib26","first-page":"15","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7","volume":"35","author":"S Mahner","year":"2017"},{"key":"10.1016\/j.ejso.2019.11.520_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ygyno.2016.12.011","article-title":"Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): a subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial","volume":"144","author":"Daniele","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib28","first-page":"1529","article-title":"Morbidity and survival of patients treated for an advanced ovarian cancer by retroperitoneal lymphadenectomy: caraco, a French randomized trial","volume":"27","author":"I Jaffre","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.11.520_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamaoncol.2016.4411","article-title":"Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the national cancer database","volume":"3","author":"Rauh-Hain","year":"2017","journal-title":"JAMA oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib30","series-title":"Report of the interval debulking surgery (IDS) safety outcome Annals of oncology Conference: 41st european society for medical oncology congress","article-title":"The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC)","author":"Ferron GR","year":"2016"},{"key":"10.1016\/j.ejso.2019.11.520_bib31","series-title":"Study of Upfront surgery versus neoadjuvant chemotherapy in patients with advanced ovarian cancer (SUNNY)","author":"Group","year":"2016"},{"key":"10.1016\/j.ejso.2019.11.520_bib32","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1200\/JCO.2016.68.1239","article-title":"Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer","volume":"34","author":"Meyer","year":"2016","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clini Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ejso.2019.11.520_bib33","doi-asserted-by":"crossref","first-page":"S952","DOI":"10.1245\/s10434-015-4651-8","article-title":"Neoadjuvant chemotherapy followed by maintenance therapy with or without bevacizumab in unresectable high-grade serous ovarian cancer: a case-control study","volume":"22","author":"Petrillo","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ygyno.2013.08.014","article-title":"Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy","volume":"131","author":"Greimel","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2407-12-31","article-title":"Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study","volume":"12","author":"Rutten","year":"2012","journal-title":"BMC Canc"},{"key":"10.1016\/j.ejso.2019.11.520_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2011.08.014","article-title":"An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)","volume":"124","author":"Chi","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2011.02.016","article-title":"Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?","volume":"121","author":"Le","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2010.08.008","article-title":"Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971\/NCIC-CTG OV13 neoadjuvant trial","volume":"47","author":"Verleye","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2019.11.520_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejso.2019.11.520_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1006\/gyno.2002.6849","article-title":"Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study","volume":"88","author":"Chan","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.11.520_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2019.11.520_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"Onda","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2019.11.520_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.07.095","article-title":"Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept","volume":"139","author":"Petrillo","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib45","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.3802\/jgo.2018.29.e47","article-title":"Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study","volume":"29","author":"Elzarkaa","year":"2018","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamasurg.2016.0773","article-title":"Hospital and payer costs associated with surgical complications","volume":"151","author":"Healy","year":"2016","journal-title":"JAMA surgery"},{"key":"10.1016\/j.ejso.2019.11.520_bib47","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1634\/theoncologist.11-10-1089","article-title":"Treatment issues in clear cell carcinoma of the ovary: a different entity?","volume":"11","author":"Pectasides","year":"2006","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejso.2019.11.520_bib48","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2019.11.520_bib49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","article-title":"An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor","volume":"153","author":"Gore","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib50","first-page":"688","article-title":"Systematic reviews and meta-analysis: scientific rationale and interpretation","volume":"64","author":"Ferreira Gonzalez","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.ejso.2019.11.520_bib51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2015.245","article-title":"Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium","volume":"113","author":"Nagle","year":"2015","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejso.2019.11.520_bib52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002164","article-title":"Association of hospital volume and quality of care with survival for ovarian cancer","volume":"130","author":"Wright","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejso.2019.11.520_bib53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Gonzalez Martin","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.11.520_bib54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.canlet.2015.08.028","article-title":"High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation","volume":"369","author":"Gorodnova","year":"2015","journal-title":"Cancer Lett"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319314696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319314696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:33:30Z","timestamp":1760060010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798319314696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0748798319314696"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.11.520","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.11.520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}